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Background: Mental health condition (MHC) comorbidity is associated with lower intensity care in multiple clinical
scenarios. However, little is known about the effect of MHC upon clinicians’ decisions about intensifying antiglycemic
medications in diabetic patients with poor glycemic control. We examined whether delay in intensification of
antiglycemic medications in response to an elevated Hemoglobin A1c (HbA1c) value is longer for patients with
MHC than for those without MHC, and whether any such effect varies by specific MHC type.
Methods: In this observational study of diabetic Veterans Health Administration (VA) patients on oral antiglycemics
with poor glycemic control (HbA1c ≥8) (N =52,526) identified from national VA databases, we applied Cox regression
analysis to examine time to intensification of antiglycemics after an elevated HbA1c value in 2003–2004, by MHC
status.
Results: Those with MHC were no less likely to receive intensification: adjusted Hazard Ratio [95% CI] 0.99 [0.96-1.03],
1.13 [1.04-1.23], and 1.12 [1.07-1.18] at 0–14, 15–30 and 31–180 days, respectively. However, patients with substance use
disorders were less likely than those without substance use disorders to receive intensification in the first two weeks
following a high HbA1c, adjusted Hazard Ratio 0.89 [0.81-0.97], controlling for sex, age, medical comorbidity, other
specific MHCs, and index HbA1c value.
Conclusions: For most MHCs, diabetic patients with MHC in the VA health care system do not appear to receive less
aggressive antiglycemic management. However, the subgroup with substance use disorders does appear to have
excess likelihood of non-intensification; interventions targeting this high risk subgroup merit attention.
Keywords: Psychiatric diagnosis, Diabetes mellitus/therapy, Health care delivery, Hypoglycemic agents/therapeutic use,
Veterans, Health services researchBackground
The drive to “cross the quality chasm” [1] toward better
health care for all Americans has drawn attention to vari-
ability in processes of health care as a contributor to vari-
ability in outcomes [2]. Adherence to process of care
standards for diabetes [3] (such as guidelines regarding
maintenance of good glycemic control) can reduce the toll
of diabetes on health [4,5]. However, clinicians do not
consistently intensify antiglycemic medications in those* Correspondence: susan.frayne@va.gov
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unless otherwise stated.with poor glycemic control [6]. While sometimes appro-
priate, [7] causes of non-intensification require inquiry.
Mental health condition (MHC) comorbidity could be one
cause.
There are several reasons to anticipate that clinicians
might respond less aggressively to poor glycemic con-
trol in patients with MHC. Adherence concerns, com-
munication barriers caused by clinical manifestations of
the MHC, time constraints posed by clinical complexity,
or bias towards patients perceived as “difficult” could fos-
ter non-intensification [8]. Indeed, MHC-related quality
gaps have been documented in diabetes managementLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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control, or receipt of antiglycemic medications [9-14].
However, we are aware of only one prior study that ex-
amines effect of MHC upon clinicians’ decisions about in-
tensification of antiglycemic medications following an
elevated Hemoglobin A1c (HbA1c) value [15]. It is im-
portant to determine if decisions about whether to inten-
sify antiglycemic medications contribute to the previously
documented tendency for patients with MHC to have dis-
proportionately poor glycemic control [9,16].
The Veterans Health Administration (VA) is an excel-
lent setting in which to examine this issue. It is the largest
integrated healthcare system in the United States, with
comprehensive electronic medical records. Mental illness
is more common in VA than in the general U.S. popula-
tion, [17-21] as is diabetes [22]. VA’s performance on dia-
betes quality measures has improved substantially since
tracking began in 1995 [23]. However, individual-level
variability persists in glycemic control (measured with
HbA1c tests), putting patients at risk of adverse diabetes
outcomes. MHC-related differences in intensity of dia-
betes care could contribute to such variability.
We studied a national cohort of diabetic patients treated
with oral antiglycemic agents in VA, asking:
(1) After an elevated HbA1c value (poor glycemic
control), is delay in antiglycemic medication
intensification longer for patients with MHC than
for those without MHC?
(2) Does any such effect vary by MHC type?
Methods
Overview and data sources
In this observational study, the study cohort was derived
from the Diabetes Epidemiology Cohorts (DEpiC) data-
base, a validated, cumulative census of all diabetic VA
patients [22]. Data came from VA’s National Patient Care
Database (NPCD) and Decision Support System (DSS).
We examined differences in antiglycemic intensification
for patients with versus without MHC managed with oral
antiglycemics who had suboptimal glycemic control. We
identified an elevated HbA1c value (“index HbA1c”) oc-
curring during a one-year Observation Interval (OI) from
April 1, 2003 through March 31, 2004, and examined in-
tensifications of antiglycemics in the 180 days following
the index HbA1c, i.e., in the period ending as late as
September 30, 2004. This study was approved by Stanford
University’s Administrative Panels for the Protection of
Human Subjects.
Study cohort
See Table 1 for details of cohort construction. DEpiC iden-
tified veterans as having diabetes as of the first day of fiscal
year 2003 based on receipt of VA antiglycemic treatmentin the prior year, or based on at least two instances of VA/
Medicare International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM) diagnosis
codes (250.00-250.93, 357.2, 362.0-362.02) in the prior
two years [22]. The study cohort was drawn from DEpiC
members who received oral antiglycemics from VA at
least once during the 6 months pre-OI, used VA out-
patient care in the prior year, and were alive on the first
day of the OI. We excluded institutionalized patients (the
focus was upon outpatient diabetes management) and pa-
tients with serious conditions likely to alter goals of care
(the focus was upon patients eligible for routine intensifi-
cation). For complete lab data capture, we excluded pa-
tients whose home VA facility did not submit HbA1c data
consistently to DSS, the central data repository. This step
retained data for 125 facilities (86%) and retained nearly
identical proportions of patients with and without MHC.
Finally, among patients with at least one HbA1c test
completed during the OI, we identified patients eligible
for intensification as those with at least one “qualifying”
HbA1c value ≥8.0 [15,24] during the OI. An elevated
HbA1c value was considered to be a qualifying value if no
antiglycemic intensification had occurred in the prior
3 months (since a clinician might not elect to intensify if
treatment was changed recently) and if no hospitalization
had occurred in the prior 3 months (since a clinician
might not intensify if the value reflected transient effects
of an acute inter-current illness or if treatment was altered
during an inpatient stay) and if the HbA1c test was not
obtained on a hospital admission day (for a similar rea-
son). In addition, a HbA1c test was only considered to be
a qualifying value if it was not preceded by any insulin
prescription in the prior six months. The rationale for this
additional requirement was that modifications to insulin
dose sometimes are communicated verbally and not re-
corded, so intensifications in insulin dose cannot be de-
tected reliably. The cohort was therefore composed of
patients managed exclusively on oral agents at baseline.
Like others, [15,24] we selected a threshold of 8.0 for
HbA1c. In the calendar period being examined, VA guide-
lines recommended a risk stratification approach with tar-
gets varying based upon comorbidities and life expectancy
[25]. The goal of this study was not to assess quality of
diabetes care in VA, for which a lower HbA1c threshold
would apply to many patients with diabetes. Instead the
goal was to examine differences in management as a func-
tion of MHC status among patients having a clear indica-
tion for intensification, i.e., in patients not meeting even
the conservative threshold of HbA1c <8.0, which would
apply to most individuals with diabetes.
Among the 66,798 patients meeting all these criteria,
we excluded the 12.6% with indeterminate MHC status
(n = 8,434; MHC Indeterminate group not shown in
Table 1), defined below. There were thus 58,364 patients
Table 1 Construction of study cohort
Sample size n Criterion
MHC Yes MHC No
n (%) n (%)
440,953 Diabetic veteran VA outpatient treated with oral antiglycemic (during the 6 months prior to the OI),
who was alive at start of OI and for whom MHC status can be determined
80,798 360,155
↓
427,335 VA outpatient use in OI* 80,745 346,590
100% 96%
↓
426,605 Non-institutionalized in OI† 80,344 346,261
100% 100%
↓
426,454 No data problems‡ 80,323 346,131
100% 100%
↓
366,066 No conditions likely to alter goals of care§ 67,099 298,967
84% 86%
↓
315,063 Patient’s home facility submitted usable HbA1c lab data to central data repository 57,309 257,754
85% 86%
↓
269,692 Had at least one HbA1c test completed during the OI 51,582 218,110
90% 85%
↓
Poor glycemic control: Had at least one HbA1c ≥8 during OI eligible to serve as an index HbA1c: 20,803 71,572
36% 28%
(1) no antiglycemic intensification in the 3 months prior to the HbA1c test, AND 18,802 65,458
90% 91%
(2) no hospitalization in the 3 months prior to the HbA1c test, AND 18,197 64,670
97% 99%
(3) not occurring on a hospital admission day, AND 18,180 64,629
100% 100%
58,364 (4) no insulin prescribed in the 6 months prior to the HbA1c test 11,581 46,783
64% 72%
↓
52,526 Final analytic cohort: Testing data set (90% random sample) 10,422 42,104
90% 90%
Legend: This table shows sample size at each step of cohort construction, overall and for those with/ without Mental Health Conditions; % reported in a row
refers to % of prior row remaining after applying the inclusion criterion listed in current row.
*Utilization refers to VA face-to-face outpatient care of any type; telephone, laboratory or radiology encounters did not qualify as face-to-face. Note that
percentages in each row use the number in the prior row as denominator.
†Did not spend more than half the year in a VA inpatient or long-term care setting.
‡Data quality issues such that unique identifier (scrambled social security number), date of birth or vital status was indeterminate.
§End-stage renal disease, end-stage liver disease, cancer, stroke or dementia diagnosis occurring in the two years prior to the observation interval.
Abbreviations: OI, Observation Interval (April 1, 2003 through March 31, 2004); MHC, Mental Health Condition; HbA1c, Hemoglobin A1c; VA, Veterans Health
Administration.
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domly selected one eligible high HbA1c value within
the OI as the “index HbA1c”, with the intent to identify
intensification occurring in the 180 days following thatindex HbA1c. After reserving a randomly-selected 10% of
patients for exploratory, model development analyses, the
remaining 90% represented the final analytic cohort
(n = 52,526; 10,422 MHC Yes and 42,104 MHC No).
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We used the Agency for Healthcare Research and Quality’s
Clinical Classifications Software, with minor modifications,
to map ICD-9-CM codes uniquely to ten specific MHCs:
depressive disorders, posttraumatic stress disorder
(PTSD), other anxiety disorders, adjustment disorders,
psychotic disorders, bipolar disorders, substance use
disorders, personality/conduct/impulse control disorders,
psychogenic disorders, and other mental health condi-
tions. ICD-9-CM code specifications are provided in the
Additional file 1. A patient was considered “MHC Yes” if
he/she had at least one instance of an MHC ICD-9-CM
code in the two years pre-OI, plus a confirmatory code
during the OI. This ensured MHC was present before the
index HbA1c and ongoing during the OI; requiring the
confirmatory code improves robustness of the MHC
measure [26]. Patients with no MHC ICD-9-CM in the
three-year period were “MHC No.” All others (i.e., those
with an MHC ICD-9-CM code in the two years pre-OI or
during the one year OI, but not both) were “MHC Inde-
terminate” and were excluded. This allowed direct com-
parisons between two sharply delineated groups (MHC
Yes versus MHC No), enhancing specificity of MHC sta-
tus classification.
Separate indicator variables were created for each spe-
cific MHC. For example, a patient was considered to
have “depressive disorder Yes” if he/she had at least one
instance of a depressive disorder ICD-9-CM code at
baseline and at least one confirmatory code during the
OI (versus no instance of depressive disorder in the
three-year period). Since an individual could have more
than one specific MHC, the same patient could have had
a positive indicator variable for another MHC such as
PTSD as well.
Dependent variable: intensification
An intensification was considered to have occurred during
the 180 days following the index HbA1c if (a) total daily
dose of oral antiglycemic medication (unit dose × quantity
issued ÷ days supply) was higher than total daily dose at
the time of the most recent prior prescription, (b) a new
oral antiglycemic was issued, or (c) insulin was issued,
based on VA pharmacy data. (Note: While changes to in-
sulin dose may not be detected reliably in pharmacy data,
such new insulin prescriptions should be.) An oral anti-
glycemic was “new” if time from end date of the most
recent prior prescription of that medication to start of the
next prescription of that medication exceeded 6 months:
issuing a medication—even at the same or lower dose—
following a lapse in therapy indicates active management
efforts by the clinician. We linked each index high HbA1c
value date to the dates of the most recent prior intensi-
fication and the most recent subsequent intensification,
if any.Competing variables/censoring variables
Following the index high HbA1c, a subsequent HbA1c <8.0
was treated as a competing event [27]. VA hospitaliza-
tions (admission dates), death, and no event prior to end
of OI were treated as right-censoring.
Other variables
Age, sex and race/ethnicity came from NPCD. Physical
Comorbidity Index is a count of 36 common, non-
psychiatric medical conditions developed for VA out-
patient case mix adjustment [28]. This, and variables for
specific macrovascular or microvascular conditions, were
derived from ICD-9-CM codes in the two years pre-OI.
Count of primary care visits in the year pre-OI was identi-
fied using clinic type codes.
Analysis
Descriptive cohort characteristics
In the analytic cohort, we calculated sample means or
percentages for sociodemographic characteristics, health
status, and index HbA1c value, for patients with any
MHC and for those with no MHC.
Bivariate associations: MHC status and intensification or
first event type
Using cross-tabulations, we summarized associations be-
tween MHC status (yes/no) and intensification within
14 days or within 30 days post index HbA1c, and between
MHC status and each of the following as a first event
during the OI: intensification, HbA1c <8, hospitalization,
death and none of these.
Main analyses: MHC status and intensification
In developing our model, we used the 10% random sub-
sample to assess whether assumptions of Cox regression
were met [27]. Then, in the 90% random sub-sample, we
used the fitted Cox regression model to test for associ-
ation between time to intensification (i.e., days from the
date of the index elevated HbA1c test to the date that
antiglycemic intensification first occurred) and MHC
status (MHC Yes versus MHC No). Our model treated
hospitalization, death and end of the OI without an
event as right censorings. The model controlled for
possible confounders, selected a priori based on the lit-
erature: sociodemographic characteristics of age and sex
(race/ethnicity was not included due to missingness),
health status (Physical Comorbidity Index and macro-
vascular/microvascular complications of diabetes), glycemic
severity (index HbA1c value), and facility level clustering
(125 facilities as fixed effects using 124 dummy variables).
With the large sample size (n = 52,526), statistical power
was more than adequate for detecting clinically meaningful
effect sizes.













Male, % 96.4 98.5
HEALTH STATUS
Physical comorbidity index, mean (SD)* 2.9 (1.9) 2.6 (1.8)
Medical comorbidities, %†
Macrovascular complications of diabetes 27.9 33.4
Ischemic heart disease 24.1 29.1
Peripheral vascular disease 6.3 7.7
Transient Ischemic Attack 0.6 0.5
Microvascular complications of diabetes 13.8 13.7
Retinopathy 3.6 4.4
Renal disease (other than end-stage 4.8 6.3
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logarithmic transformation of the Physical Comorbidity
Index. To meet the proportional hazards assumption
for MHC status, age and microvascular complications, we
performed interval-specific analyses, [29] dividing the
180 days following the index HbA1c into three periods:
0–14, 15–30, and 31–180 days post index HbA1c.
These periods are clinically meaningful: allowing time
for the clinician to receive the lab result, it would be
desirable for clinicians to respond to an abnormal lab
promptly within two weeks (consistent with the 0–14
day interval), but if an appointment needed to be
scheduled to review the results, it could have taken a
month to bring the patient in to the office to discuss
treatment options (consistent with the 15–30 day inter-
val). Intensifications occurring more than a month after
the elevated HbA1c may have been occurring at routine
visits not scheduled for the specific purpose of review-
ing the test result. We fit the model separately to all pa-
tients who had not yet experienced an event during
each of these three sequential time periods. In the first
two time periods, we treated a subsequent HbA1c <8.0
as a right censoring event, due to the small number of
such events (0.1% and 0.2%, respectively). In the last
model (31–180 days), we treated a subsequent below-
threshold HbA1c value as a competing event; we pos-
tulated that once HbA1c <8.0 occurred, a search for
subsequent intensification was no longer necessary.
For all models, attainment of the end of the time
period of interest without an event was treated as an
administrative right censoring event.
Reported parameter estimates are from the fit to the
90% sample. From the covariate-adjusted Cox regression
models, primary parameter values of interest were hazard
ratios (HR), estimated for intensification as a function of
MHC status. We also estimated cumulative incidence
functions, [30] separately by MHC status (yes/no) and
time period (0–14, 15–30, 31–180 days), with all covari-
ates set to their sample means. Cumulative incidence
functions were estimated for the below-threshold HbA1c
value competing event for 31–180 days only.renal disease)
Peripheral neuropathy 6.9 4.6






*Selim Comorbidity Index, physical component, is a count of 36 common
non-psychiatric medical conditions.
†Comorbidities present in the 2 years prior to the Observation Interval.
Abbreviations: MHC, Mental Health Condition; HbA1c: Hemoglobin A1c;
SD, Standard Deviation.Secondary analyses: specific MHCs and intensification
We then repeated the same Cox regression analysis ex-
cept that we included ten binary indicator variables for
the ten most prevalent specific MHCs (depressive dis-
orders, PTSD, other anxiety disorders, adjustment dis-
orders, psychotic disorders, bipolar disorders, substance
use disorders, personality or conduct/impulse control
disorders, psychogenic disorders, and other MHCs) in a
single model, making it possible to examine the distinct
contribution of each individual MHC in the context of




In the analytic cohort, 10,422 patients had MHC, and
42,104 had no MHC. Sample mean (SD) age was 58.3
(9.4) and 65.4 (10.6) years, respectively (p <0.001). Sam-
ple mean (SD) number of primary care visits in the
365 days before the index HbA1c was 4.3 (3.6) and 3.4
(2.7), respectively (p <0.001). Table 2 shows estimates
for patient characteristics, by MHC status. The most com-
mon specific MHCs were depressive disorders (9.7%),
PTSD (6.1%), other anxiety disorders (2.5%), adjustment
disorders (0.5%), psychotic disorders (2.5%), bipolar
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ity or conduct/impulse control disorders (0.4%), psycho-
genic disorders (0.2%) and all other MHCs (0.2%). Among
patients with any MHC, 7,131 (68.4%) had exactly one of
the 10 specific MHCs examined; others had at least two of
these MHCs.Bivariate associations: MHC status and intensification or
first event type
Intensification occurred within 14 days for 39.0% of pa-
tients with MHC and 37.9% of those without MHC,
and within 30 days for 46.3% and 44.2%, respectively
(Table 3). Intensification was the first event after the
index high HbA1c for an estimated 64.7% and 61.0%,
respectively. HbA1c <8.0 was the first event for 9.6%
and 9.8%, respectively. Hospitalization was the first
event for 4.3% and 2.1%, respectively; <1% of hospitali-
zations were for indications potentially proximately re-
lated to level of glycemic control, e.g., hospitalizations
for hyperglycemia or hypoglycemia.Main analyses: MHC status and intensification
No difference was detected in rate of intensification in
the first 14 days after a high HbA1c value between pa-
tients with versus without MHC, after controlling for
patient characteristics and facility (HR 0.99) (Table 4).
Patients with MHC were estimated to experience a
somewhat higher rate of intensification of antiglycemic
medications than were those without MHC during the
15–30 and the 31–180 days following a high HbA1c
(HR 1.13 and HR 1.12, respectively).Table 3 Intensification (or alternate events) after an
elevated HbA1c Value, by presence of a mental health
condition, unadjusted*




TIME TO ANTIGLYCEMIC INTENSIFICATION
Intensification occurred within 14 days after
high HbA1c, %
39.0 37.9
Intensification occurred within 30 days after
high HbA1c, %
46.3 44.2
FIRST EVENT AFTER INDEX HBA1C VALUE
First event, %
Intensification 64.7 61.0
HbA1c value <8.0 9.6 9.8
Hospitalization 4.3 2.1
Death 0.2 0.5
No event following index HbA1c 21.2 26.5
* These unadjusted analyses are presented for descriptive purposes, so no
P-values are presented.
Abbreviations: MHC, Mental Health Condition; HbA1c, Hemoglobin A1c.While not a focus of this paper, it is noteworthy that
in each time interval following an elevated HbA1c value,
older patients were estimated to experience a somewhat
lower rate of intensification than younger patients. No
independent effect of patient sex was identified, though
the number of women was relatively small. Not surpris-
ingly, patients with progressively worse glycemic control
in general were estimated to experience a progressively
higher rate of intensification than patients with better
glycemic control.
These patterns related to MHC were also evident in
the estimated cumulative incidence functions. That is,
during the later two time periods, intensification events
accumulated more rapidly for those with MHC than for
those with no MHC (Figure 1).
Secondary analyses: specific MHCs and intensification
As Table 5 shows, we detected a higher rate of intensifica-
tion among patients with depressive disorders at 15–30
days (HR 1.21, CI 1.08-1.36) and at 31–180 days (HR
1.12, CI 1.04-1.21), versus those with no depressive dis-
order. Similarly, we saw a higher rate of intensification
among patients with psychogenic disorders versus those
with no psychogenic disorder, at 31–180 days (HR 1.79,
CI 1.21-2.64). In contrast, rate of intensification was es-
timated to be lower for patients with substance use disor-
ders at 0–14 days (HR 0.89, CI 0.81-0.97) versus those
without substance use disorders. Other differences for
specific MHCs were not statistically significant.
Discussion
Contrary to our hypothesis, we found diabetic patients
with mental health conditions were no less likely to re-
ceive intensification of antiglycemic medications in re-
sponse to an elevated HbA1c value than were those
without MHC. Indeed, among diabetic patients who did
not receive intensification within the first two weeks fol-
lowing a high HbA1c value, those with MHC were mar-
ginally more likely than those with no MHC to receive
intensification. A similar effect appeared to hold for de-
pressive disorders and, in the 31–180 days following an
elevated HbA1c value, for psychogenic disorders. In con-
trast, patients with substance use disorders were less
likely than those with no substance use disorder to receive
intensification in the first two weeks following a high
HbA1c value, controlling for sex, age, medical comorbid-
ity, other specific MHCs, index HbA1c value, and facility.
These findings reinforce mounting evidence that the
relationship between MHC and intensity of medical care
might be more complex than initially appeared. Multiple
studies have concluded that patients with MHC receive
less intensive medical care. This has been seen for processes
and intermediate outcomes of care in a range of conditions,
from cardiovascular disease [13,31] to preventive care [32]
Table 4 Hazard ratios for antiglycemic intensification, and for the competing event, in the main model that examines
MHC in aggregate*
0-14 days 15-30 days 31-180 days
Parameter† HR 95% CI HR 95% CI HR 95% CI
MAIN ANALYSIS (Outcome: Intensification)
MHC (1 = yes, 0 = no) 0.99 0.96-1.03 1.13 1.04-1.23 1.12 1.07-1.18
Index HbA1c value 9–9.9‡ 1.24 1.20-1.28 1.38 1.27-1.50 1.36 1.29-1.43
Index HbA1c value 10–10.9 1.32 1.26-1.38 1.29 1.15-1.45 1.49 1.40-1.59
Index HbA1c value 11–11.9 1.47 1.39-1.56 1.68 1.46-1.94 1.65 1.51-1.81
Index HbA1c value 12.0+ 1.57 1.47-1.67 1.47 1.25-1.73 1.65 1.49-1.82
Sex (1 = male, 0 = female) 0.98 0.89-1.08 0.92 0.73-1.17 0.89 0.77-1.02
Log physical comorbidity index 1.01 0.98-1.04 1.03 0.95-1.11 1.24 1.18-1.30
Age (per 10 years) 0.95 0.94–0.97 0.95 0.92-0.99 0.93 0.91-0.95
Any macrovascular comorbidity 1.01 0.98-1.04 1.04 0.96-1.12 1.03 0.98-1.08
Any microvascular comorbidity 0.95 0.91-0.99 0.95 0.86-1.05 1.15 1.08-1.22
COMPETING EVENT (CE) ANALYSIS (Outcome: HbA1c value <8.0)
MHC (CE) (1 = yes, 0 = no) 1.16 1.08-1.25
Index HbA1c value 9–9.9 (CE)‡ 0.56 0.51-0.60
Index HbA1c value 10–10.9 (CE) 0.31 0.27-0.36
Index HbA1c value 11–11.9 (CE) 0.28 0.22-0.35
Index HbA1c value 12.0+ (CE) 0.24 0.18-0.32
Sex (CE) (1 = male, 0 = female) 1.08 0.86-1.35
Log physical comorbidity index (CE) 1.29 1.21-1.37
Age (per 10 years) (CE) 0.99 0.96-1.02
Any macrovascular comorbidity (CE) 0.95 0.89-1.01
Any microvascular comorbidity (CE) 1.10 1.02-1.20
Legend: This table shows Hazard Ratios for intensification of antiglycemic medications in the 0–14, 15–30 and 31–180 days following HbA1c value ≥8.0, and for
the competing event (HbA1c value <8.0) in the 31–180 days following HbA1c value ≥8.0.
*Hazard Ratios (HR) with statistically significant p-values (at p < .05) are shown in bold type face. Here “hazard rate” is the instantaneous rate of an event among
those who have not experienced an event. The ratio of these rates under two different conditions is the “hazard ratio” (e.g., with MHC versus without MHC).
†In the 0–14 day and 15–30 day models, hospitalization, death, subsequent HbA1c value <8.0 and end of the specific interval without an event are treated as
censoring variables. In the 31–180 day model, hospitalization, death and end of the interval without an event are treated as censoring variables, and subsequent
HbA1c value <8.0 is treated as a competing event (with Hazard Ratios for the competing event shown in the lower half of the table). All analyses also control for
the 125 VA facilities, through 124 individual dummy variables; the hazard ratios for each of those facilities are not shown in this table, for parsimony. The overall
P-value for the facilities effect is <0.001 in each of the three time intervals.
‡Reference group for Index HbA1c value is HbA1c value of 8–8.9.
Abbreviations: MHC, Mental Health Condition; HbA1c, Hemoglobin A1c; HR, Hazard Ratio; CI, Confidence Interval; CE, Competing Event analysis.
Frayne et al. BMC Health Services Research 2014, 14:458 Page 7 of 13
http://www.biomedcentral.com/1472-6963/14/458to diabetes [9-12,33]. Despite consistency of such findings,
null effects and counter-effects have also been appearing in
the literature [14,15,34-36].
What might account for this inconsistency? One factor
may be that MHCs represent a heterogeneous group of
clinically distinct conditions. Many studies aggregate
MHCs, reducing ability to detect more granular effects. In
studies that do distinguish between different MHCs, sub-
stance use disorders frequently emerge as drivers of low
intensity care [9,10]. Such was the case in our study as
well: we estimated a lower rate of antiglycemic intensifica-
tion in the first two weeks after a high HbA1c among pa-
tients with substance use disorders. While our study was
not designed to identify mechanisms, this finding couldreflect patient non-adherence leading clinicians to advise
patients to use the currently-prescribed dose more regu-
larly, [37] patients’ failure to attend scheduled follow-up
appointments to discuss medication modifications, [38]
clinician concerns about risk of hypoglycemia related to
drug interactions or unreliable timing of medication in-
take, [39] or clinician bias leading to altered prescribing
patterns [40].
Another potential contributor to observed inconsist-
ency between studies examining medical care intensity
for patients with MHC relates to differences in how care
intensity was measured. Some prior studies focused on
factors like level of glycemic control, which might be
sensitive to patient behaviors outside the medical visit.
Figure 1 Cumulative incidence functions for time to intensification following a high HbA1c value. This figure shows estimated cumulative
incidence functions derived from the Cox regression cause-specific hazards (adjusted for confounders at their sample mean values) for time to
intensification following a high HbA1c value. Estimates are presented by Mental Health Condition status, within each of three time intervals (0–14
days, 15–30 days, 31–180 days), for the analytic cohort of diabetic patients (n =52,526). The 31–180 day cumulative incidence function is structured as
a competing events analysis, with HbA1c <8.0 as a competing event. Each estimated cumulative incidence function gives the estimated cumulative
probability of experiencing a particular event type (e.g., intensification) first up to that point in time. These cumulative probabilities do not reach 1 at
the end of each time period (right side of each graph) due to right censoring and, during the period of 31 to 180 days, due to the concurrent
accumulation of incidences of the competing event.
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http://www.biomedcentral.com/1472-6963/14/458In contrast, medication intensification, the focus of our
study, may be more responsive to health care utilization
patterns [36]. In our study, patients with MHC used pri-
mary care services more heavily in the year before the
index HbA1c value; assuming such utilization patterns
continued following the index HbA1c value, the patientswith MHC might have had more opportunities to re-
ceive medication intensification. We found patients with
and without MHC were equally likely to receive intensi-
fication in the first two weeks after a high HbA1c but
that patients with MHC were more likely to receive in-
tensification thereafter. This could mean that in the
Table 5 Hazard ratios for antiglycemic intensification, and for the competing event, in the secondary model that
examines the distinct contribution of each of the ten specific MHCs*
0-14 days 15-30 days 31-180 days
Parameter† HR 95% CI HR 95% CI HR 95% CI
MAIN ANALYSIS
(Outcome: Intensification)
Depressive disorder (1 = yes, 0 = no) 1.01 0.99-1.09 1.21 1.08-1.36 1.12 1.04-1.21
PTSD 0.99 0.93-1.05 1.09 0.95-1.25 1.01 0.92-1.10
Anxiety disorder 1.01 0.92-1.11 0.89 0.71-1.12 1.10 0.97-1.26
Adjustment disorder 1.02 0.85-1.23 0.66 0.39-1.12 1.20 0.93-1.55
Psychotic disorder 0.92 0.84-1.01 1.01 0.83-1.25 1.06 0.94-1.20
Bipolar disorder 1.00 0.88-1.13 1.03 0.77-1.39 1.08 0.90-1.30
Substance use disorder 0.89 0.81-0.97 0.95 0.76-1.17 1.08 0.95-1.23
Personality/Impulse/Conduct disorder 0.88 0.71-1.10 1.17 0.75-1.84 0.86 0.63-1.18
Psychogenic disorder 1.27 0.95-1.69 0.88 0.39-1.97 1.79 1.21-2.64
Other MHC 1.15 0.86-1.53 1.49 0.80-2.79 1.03 0.64-1.64
Index HbA1c value 9–9.9‡ 1.24 1.20-1.28 1.38 1.27-1.50 1.34 1.29-1.43
Index HbA1c value 10–10.9 1.32 1.26-1.38 1.29 1.15-1.45 1.49 1.40-1.59
Index HbA1c value 11–11.9 1.48 1.39-1.57 1.68 1.46-1.94 1.65 1.51-1.81
Index HbA1c value 12.0+ 1.57 1.48-1.67 1.47 1.25-1.73 1.65 1.50-1.82
Sex (1 = male, 0 = female) 0.98 0.89-1.09 0.93 0.73-1.17 0.90 0.78-1.03
Log physical comorbidity index 1.00 0.97-1.04 1.03 0.96-1.11 1.24 1.18-1.30
Age (per 10 years) 0.95 0.94-0.96 0.95 0.92-0.99 0.93 0.91-0.95
Any macrovascular comorbidity 1.01 0.98-1.04 1.03 0.96-1.12 1.03 0.98-1.08
Any microvascular comorbidity 0.95 0.91-0.99 0.95 0.86-1.05 1.15 1.08-1.22
COMPETING EVENT (CE) ANALYSIS
(Outcome: HbA1c value <8.0)
Depressive disorder (CE) (1 = yes, 0 = no) 1.08 0.97-1.20
PTSD (CE) 1.01 0.89-1.14
Anxiety disorder (CE) 1.23 1.04-1.46
Adjustment disorder (CE) 1.39 0.99-1.94
Psychotic disorder (CE) 1.30 1.09-1.55
Bipolar disorder (CE) 1.20 0.93-1.55
Substance use disorder (CE) 0.98 0.80-1.20
Personality/Impulse/Conduct disorder (CE) 0.83 0.51-1.34
Psychogenic disorder (CE) 1.19 0.57-2.51
Other MHC (CE) 1.49 0.86-2.59
Index HbA1c value 9–9.9 (CE) ‡ 0.56 0.51-0.60
Index HbA1c value 10–10.9 (CE) 0.31 0.27-0.36
Index HbA1c value 11–11.9 (CE) 0.28 0.22-0.35
Index HbA1c value 12.0+ (CE) 0.24 0.18-0.32
Sex (CE) (1 = male, 0 = female) 1.10 0.88-1.37
Log Physical Comorbidity Index (CE) 1.29 1.21-1.37
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Table 5 Hazard ratios for antiglycemic intensification, and for the competing event, in the secondary model that
examines the distinct contribution of each of the ten specific MHCs* (Continued)
Age (per 10 years) (CE) 0.98 0.96-1.01
Any macrovascular comorbidity (CE) 0.95 0.89-1.01
Any microvascular comorbidity (CE) 1.11 1.02-1.20
Legend: This table shows Hazard Ratios for intensification of antiglycemic medications in the 0–14, 15–30 and 31–180 days following HbA1c value ≥8.0, and for
the competing event (HbA1c value <8.0) in the 31–180 days following HbA1c value ≥8.0. The model includes ten binary indicator variables for the ten most
prevalent specific MHCs (depressive disorders, PTSD, other anxiety disorders, adjustment disorders, psychotic disorders, bipolar disorders, substance use disorders,
personality or conduct/impulse control disorders, psychogenic disorders, and other MHCs) all in a single model.
*Hazard Ratios (HR) with statistically significant p-values (at p < .05) are shown in bold face. Here “hazard rate” is the instantaneous rate of an event among those
who have not experienced an event. The ratio of these rates under two different conditions is the “hazard ratio”.
†In the 0–14 day and 15–30 day models, hospitalization, death, subsequent HbA1c value <8.0 and end of the specific interval without an event are treated as
censoring variables. In the 31–180 day model, hospitalization, death and end of the interval without an event are treated as censoring variables, and subsequent
HbA1c value <8.0 is treated as a competing event (with Hazard Ratios for the competing event shown in the lower half of the table). All analyses also control for
the 125 VA facilities, through 124 individual dummy variables; the hazard ratios for each of those facilities are not shown in this table, for parsimony. The overall
P-value for the facilities effect is <0.001 in each of the three time intervals.
‡Reference group for Index HbA1c value is HbA1c value of 8–8.9.
Abbreviations: MHC, Mental Health Condition; PTSD, Posttraumatic stress disorder; HbA1c: Hemoglobin A1c; HR, Hazard Ratio; CI, Confidence Interval; CE, Competing
Event analysis.
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http://www.biomedcentral.com/1472-6963/14/458absence of a prompt response to a high HbA1c, clini-
cians are more liable to take action in patients they see
more frequently. The observation that patients with
more physical comorbidity were similarly more likely to
receive intensification at 31–180 days – as were patients
with psychogenic disorders – bolsters this supposition.
Still another potential contributor to our finding that
presence of MHC did not reduce a patient’s chances of
antiglycemic intensification could relate to treatment of
the MHC itself, especially in a setting like VA where men-
tal health services are available at every medical center.
The clinical presentation of patients with treated MHC
(i.e., with good MHC symptom control) could resemble
that of patients without MHC, attenuating differences in
intensification. Indeed, treating MHC can result in im-
proved medical outcomes [41].
This study has several strengths. First, it includes essen-
tially the universe of diabetic patients on VA-prescribed
oral agents with poor glycemic control, making findings
more representative than would be possible in studies
examining a specific setting or using primary data collec-
tion methodologies. Second, care was taken to identify
sharply drawn cohorts of patients with and without MHC,
reducing misclassification risk. Third, this study examines
a range of MHCs and thus complements the one similar
study we are aware of, which focused on depression
[15]. Fourth, the longitudinal analysis approach, which
accounted for competing and censoring events, allowed
for more robust conclusions because the temporally dy-
namic nature of patient status was taken into account.
Despite these strengths, findings in this study must be
interpreted subject to several caveats. First, this study used
existing data. This could have led to incomplete capture
of intensifications, if verbal dosage changes were not
promptly recorded or if some patients received supple-
mental prescriptions outside VA, although VA medicationpricing structures would generally make this less likely.
Nonpharmacological treatments (lifestyle modification
counseling) likewise would not be captured in these data,
although VA encourages such counseling for all patients
with diabetes. Use of existing data also could have led to
under-ascertainment of MHC, [42] although VA requires
routine screening for depression, PTSD and alcohol use
disorder; like this study, many studies examining quality
of care for patients with MHC use ICD-9-CM codes to
identify MHCs [8,31]. Models do not include an indicator
for receipt of psychiatric medications, some of which can
worsen glycemic control and which would therefore be
expected to increase clinicians’ vigilance about monitoring
glycemic state and responding to above-target HbA1c
values. Severity of MHC likewise is not captured, and
models do not control for patient preferences (not avail-
able in these databases). Second, our study examined
intensifications. If a patient was nonadherent to a
previously-prescribed medication, the provider would
appropriately focus on adherence, rather than dose es-
calation. Third, comorbidities were set to their base-
line value (present/absent) rather than treating them as
time-dependent variables. Any bias thus introduced
[43] should be small, since new onset of chronic condi-
tions during the narrow OI is expected to be low. Fourth,
events have been modeled as non-terminal competing
events, [44] focusing on time to first event. This approach
was appropriate to the study question examining clin-
ical reactions proximal to an elevated HbA1c, but does
not capture subsequent events. Fifth, the OI for this
study ended in 2004. Diabetes management guidelines
regarding target HbA1c value have evolved since then,
so absolute rates of intensification in reaction to an ele-
vated HbA1c may not entirely reflect current practice.
However, the focus of this study was not upon absolute
rates but rather upon differences in how clinicians react
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have evolved over this time period. Sixth, the study sample
came from all diabetic patients in VA who were being
managed exclusively on oral antiglycemics. Because we
excluded those who received any insulin during the
prior six months, our cohort, while focusing on poorly-
controlled diabetes, may have tended to exclude those
with particularly labile glycemic control. The study sample
is substantially smaller than the base cohort, but that is
largely because the research question is only clinically
relevant to those with elevated HbA1c. Seventh, 90% of
patients with MHC and 85% of those without MHC re-
ceived HbA1c testing, and thus had an opportunity to
have poor glycemic control detected, if present. However,
this study did not capture the relatively small group with
no HbA1c testing—this may have represented patients
with relatively stable diabetes (who did not need to be
tested as frequently), patients not being carefully moni-
tored, patients who did not go to the lab to complete an
ordered HbA1c test, or patients receiving most of their
care outside of VA. Finally, since the VA has strong sys-
tems of care for both medical and mental health condi-
tions, study findings might not be generalizable to
veterans not using VA, or to non-veterans. Results from
this predominantly male sample also may not generalize
to women.
Conclusions
Our findings offer a mixed message. On one hand, it is
reassuring that antiglycemic medication management
appears to be at least as intensive for patients with
MHC as for those without MHC, especially for depres-
sion, one of the most common MHCs in the United
States [45]. On the other hand, less than half of patients
received intensification in the first month after a high
HbA1c. While antiglycemic intensification is sometimes
clinically inappropriate even for a substantially elevated
HbA1c, this study of 2003-2004 care does raise the
possibility of room for performance improvement inde-
pendent of mental health comorbidity status, consistent
with studies documenting “clinical inertia” in many
health care settings [4,6,46]. Furthermore, the subgroup
with substance use disorders may be at risk for less in-
tensive antiglycemic care, which may or may not be ap-
propriate, depending on the clinical scenario. Clinicians
should carefully consider the appropriate response to
an elevated HbA1c value, particularly in patients with
substance use disorders. Future studies should examine
the potential benefits of interventions specifically targeting
diabetes management in this subgroup, such as collabora-
tive care models between primary care providers and
specialty substance use disorder treatment providers, or
primary care medical home models that include embed-
ded mental health professionals [47,48].Additional file
Additional file 1: ICD-9-CM code specifications for Mental Health
Conditions.
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